Abstract
Background: The p16 gene (CDKN2), a tumor suppressor gene located on chromosome 9p21, has been demonstrated to be mutated or deleted with high frequency in a variety of tumor cell lines, including breast. While previous studies have not demonstratedCDKN2 mutations in primary breast carcinomas, it is possible that gene deletion in neoplastic DNA was masked by the presence of contaminating normal stromal DNA in breast carcinoma specimens.
Methods: We investigated the incidence of homozygous deletion ofCDKN2 by analyzing 20 microdissected pure populations of primary breast carcinoma cells. Using polymerase chain reaction (PCR) techniques, the entire coding region and intervening introns ofCDKN2 were amplified. The PCR products were resolved by agarose gel electrophoresis and single-strand conformation polymorphism (SSCP) analysis.
Results: We detected no deletions or mutations of the p16 gene.
Conclusions: CDKN2 is not deleted with high frequency in primary breast carcinomas, and the p16 gene does not play a role in breast carcinogenesis via this mechanism.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996.CA Cancer J Clin 1996;65:5–27.
Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, et al. A cell cycle regulator potentially involved in genesis of many tumor types.Science 1994;264:436–40.
Koh J, Enders GH, Dynlacht BD, Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition.Nature 1995;375:506–10.
Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers.Nature 1994;368:753–6.
Rush EB, Abouezzi Z, Borgen PI, Anelli A. Analysis of MTS1/CDK4 in female breast carcinomas.Cancer Lett 1995;89:223–6.
Xu L, Sgroi D, Sterner CJ, Beauchamp RL, Pinney DM, Keel S, Ueki K, et al. Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas.Cancer Res 1994;54:5262–4.
Youngson BJ, Anelli A, Van Zee KJ, Borgen PI, Norton L, Rosen PP. Microdissection and molecular genetic analysis of HER2/neu in breast carcinoma.Am J Surg Pathol 1995;19:1354–8.
Hussussian CJ, Struewing JP, Goldstien AM, Higgins PAT, Ally DS, Sheahan MD, Clark WH Jr, et al. Germline p16 mutations in familial melanoma.Nat Genet 1994;8:15–20.
Gruis NA, Weaver-Feldhaus J, Liu Q, Frye C, Eeles R, Orlow I, Lacombe L, et al. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression.Am J Pathol 1995;146:1199–206.
Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma.Nat Genet 1994;8:27–32.
Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger P, Baylin SB, et al. 5′CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.Nat Med 1995;1:686–92.
Herman JG, Merlo A, Mao L, Lapidus RG, Issa J-PJ, Davidson NE, Sidransky D, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.Cancer Res 1995;55:4525–30.
Zulueta-Gonzalez M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA. Methylation of the 5′CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.Cancer Res 1995;55:4531–5.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Calvano, J.E., Rush, E.B., Tan, L.K. et al. Absence of p16 gene (CDKN2) deletions in microdissected primary breast carcinoma specimens. Annals of Surgical Oncology 4, 416–420 (1997). https://doi.org/10.1007/BF02305555
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02305555